Population-level data highlight varied risk profiles among patients with indolent systemic mastocytosis (ISM), highlighting the need for individualized treatment approaches, according to Sudipto Mukherjee, MD, PhD, MPH, a physician in the department of hematology and medical oncology at Cleveland Clinic.
A groundbreaking study led by Sudipto Mukherjee, MD, PhD, MPH, a physician in the department of hematology and medical oncology at Cleveland Clinic, sheds light on the diverse survival outcomes among patients with indolent systemic mastocytosis (ISM).
The findings underscore the need for further genomic research to better understand the underlying mechanisms driving disease progression and mortality in this patient population.
Transcript
What are the potential implications of your findings and how might the identification of specific patient characteristics or disease features and mortality inform future approaches to managing patients with ISM?
I think these results are definitely eye opening and should be factored in for any clinical practitioner managing systemic mastocytosis patients in daily clinical practice. This is probably the first and the largest population-level data on survival in ISM in the US, and it is clearly telling us that the [ISM] diagnostic entity is not a homogeneous entity. In fact, it has a wide phenotypic spectrum, with certain patients at a higher risk of progression to advanced disease and with higher mortality. And we also know from our prior work that not all patients [with ISM] behave the same way. There is a certain subset of patients who have a pretty high symptom burden compared to those with a lower symptom burden. I think the focus is to be aware when counseling these patients that not all patients [with ISM] are the same. Specifically, that not all of them are going to have a clinically indolent course, meaning they will not have an asymptomatic or minimally symptomatic disease lasting for a decade or so. Some of them will definitely be progressed to advance disease sooner rather than later and the overall mortality, irrespective of whether you have evidence of disease progression or not, is definitely inferior compared to the general population.
So, having that awareness is important, because that should factor in how frequently and closely they need to be monitored. And second, we need to find out what there are the biological or are there any genomic underlying causes that can explain why some progress faster and some progress at a slower rate. So, I think a much more in-depth, genomic understanding of these subset of patients [with ISM] who progress faster or have higher mortality needs to be done. And this study should trigger those subsequent studies from happening.
We do have tyrosine kinase inhibitors that are approved for patients with [ISM]. And this population-level study does provide very significant evidence and an impetus to consider treating these patients [with ISM] with a tyrosine kinase inhibitor, because that may mitigate the development of complications down the line. It’s still too early, but it may hopefully extend survival, especially in the group of patients [with ISM] who we do see in our analysis who happen to have a significant mortality, even in the first few years following the diagnosis.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Bridging Care Gaps With a Systemwide Value-Based Care Strategy
March 29th 2025Mapping care management needs by defining patient populations and then stratifying them according to risk and their needs can help to spur the transformation of a siloed health care system into an integrated system that is able to better provide holistic, value-based care despite the many transitions that continue among hospital, primary, specialty, and community care environments.
Read More
Understanding Primary and Secondary Nonadherence to Chronic Oral Medication
March 28th 2025Medication nonadherence to oral anticoagulants and oral anti–prostate cancer medication has been scrutinized through new research conducted among patients and health care providers and presented by the American Medical Group Association at its 2025 annual meeting, held March 26-29 in Grapevine, Texas.
Read More
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More